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http://dx.doi.org/10.1016/j.jtho.2015.08.001One major advance of the past decade in anticancer
treatment is the advent of precision medicine and
personalized therapy, which has led to several thera-
peutic successes.1,2 The efﬁcacy of targeted therapies is
unavoidably limited in time, however, and acquired
resistance ultimately occurs.
Here, we report the case of a 59-year-old white
woman with no smoking history who was diagnosed
with metastatic adenocarcinoma of the lung. At diag-
nosis, restricted molecular analysis of the primary tu-
mor showed epidermal growth factor receptor (EGFR),
B-Raf proto-oncogene, serine/threonine kinase (BRAF),
and Kristen rat sarcoma viral oncogene homolog
(KRAS) wild type and the absence of anaplastic lym-
phoma kinase (ALK) translocation. After three lines of
conventional therapy, she was included in a phase 1
trial evaluating a gamma secretase inhibitor, during
which the disease remained stable for 18 months. A
second lung biopsy sample (containing 40% tumor
cells) was then obtained as part of the MOSCATO
(Molecular Screening for Cancer Treatment Optimiza-
tion) trial at Gustave Roussy Cancer Campus
(NCT01566019). Comparative genomic hybridization
analyses revealed an MDM2 proto-oncogene, E3 ubiq-
uitin protein ligase (MDM2) ampliﬁcation, and targeted
next-generation sequencing showed a MET proto-
oncogene, receptor tyrosine kinase (MET) activating
mutation (NM_001127500.1:c.3082G>C; p.Asp1028His
or p.D1028H, allele frequency 18%).On the basis of this molecular proﬁle, crizotinib
(Xalkori, Pﬁzer) was initiated as part of the basket AcSé
Crizotinib trial (NCT02034981). Crizotinib resulted in a
56% reduction in size of the target lesions that was
followed by progression of the disease 10 months later
(Fig. 1). The patient was then enrolled in the MATCH-R
(A Prospective Trial to Study the Evolution of Clonal
Architecture of Tumors from Patients Treated with
Molecular Targeted Agents) trial at Gustave Roussy
Cancer Campus, in which next-generation sequencing,
comparative genomic hybridization, and patient-
derived xenografts from tumors that progress during
administration of targeted therapy (ID-RCB number:
2014-A01147-40) are performed. Biopsy of the pro-
gressing pulmonary lymph node (containing 70% tu-
mor cells) revealed a novel EGFR ampliﬁcation (log
ratio 1.21) associated with an activating mutation of
EGFR located in a hot spot codon of p.Leu861ArgJournal of Thoracic Oncology Vol. 11 No. 2: e21-e23
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Figure 1. Patient 1: clinical course, including treatment history and relevant imaging studies and tumor biopsy specimens.
Representative images from computed tomography of the chest at different times: (A) at baseline (before administration of
crizotinib), showing right pulmonary lesion; (B) at 3 months, with an excellent tumor response in right pulmonary lesion; and
(C) at 10 months, with tumor progression. Abbreviations: DOC, docetaxel; EGFR, epidermal growth factor receptor; GEM,
gemcitabine; KRAS, Kirsten rat sarcoma viral oncogene homolog; M, months; MIP, mitomycin-ifosfamide-cisplatin; NOTCHi,
inhibitor of the Notch pathway; PAC-BEV, paclitaxel-bevacizumab; PEM, pemetrexed; WT, wild-type.
e22 Benderra et al Journal of Thoracic Oncology Vol. 11 No. 2(p.L861R, allele frequency 53%) activating mutation on
exon 21. The p.D1028H MET mutation was still present
(allele frequency 6%). Given this molecular proﬁle and
the patient’s resistance to crizotinib, administration ofFigure 2. Signaling pathways activated by hepatocyte growth
growth factor receptor-bound protein 2 (GRB2) and GRB2-associ
Abbreviations: AKT, protein kinase B; ERK, extracellular signa
mitogen-activated protein kinases; mTOR, mammalian target o
tidyl inositol 3-OH-kinase; VEGFR, vascular endothelial growththe epidermal growth factor receptor (EGFR) inhibitor
geﬁtinib was initiated.
Crizotinib is registered primarily for ALK-translocated
non–small cell lung cancer. Therefore, most resistancefactor and MET. Cytoplasmic effector molecules, including
ated binding protein (GAB1) are recruited to the docking site.
l-regulated kinase; HGF, hepatocyte growth factor; MAPK,
f rapamycine; NfkB, nuclear factor kappa B; PI3K, phospha-
factor receptor.
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include the following: secondary ALK mutations (28%),
ALK copy number gain (18%), EGFR mutations (36%,
mainly exon 20 p.S768I and exon 21 p.L858R mutations),
and rare KRASmutations.3 Approximately one-ﬁfth of the
resistance mechanisms remain unknown. Interestingly,
crizotinib was initially developed as aMET inhibitor,4 and
some clinical trials are still evaluating it for that indication
(NCT00585195). MET exon14 alterations (4% of adeno-
carcinomas of the lung5) lead to crizotinib sensitivity.6
Whether mechanisms of resistance to crizotinib used in
a MET-mutated population are the same as those in an
ALK-translocated population is still unknown (Fig. 2).
Logic would suggest that they could be divided into two
groups: speciﬁc resistance mechanisms (consisting of
mutation of the kinase domain of the target of interest,
ALK or MET, respectively), and common resistance
mechanisms, which would include the activation of
alternative pathways to bypass inhibition of the oncogenic
driver. Interestingly, the EGFR mutation described here
had not been observed previously in the crizotinib-
resistant ALK-translocated population, which suggests
greater “target speciﬁcity” of the resistance mechanisms.
This case also illustrates the challenges of tumors’
temporal and spatial heterogeneity: the fact that
despite a deep coverage of 3086 X at the corre-
sponding position, the EGFR p.L861R mutation was not
detected at the initiation of crizotinib therapy does not
rule out the possibility that it was already present at
another tumor location or at undetectable levels in a
subclone.
In summary, here we have described a previously
unreported EGFR activating hot spot mutation as anacquired mechanism of resistance to crizotinib in a
MET-mutated non–small cell lung cancer tumor. This il-
lustrates the importance of repeated molecular proﬁling
in precision medicine.Acknowledgment
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